Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 6/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3081603 | 1.00 | SLC18A3 (0.46) | SLC18A3CA1CA2CA4TSHR | |
| SCHEMBL3088065 | 1.00 | SLC18A3 (0.46) | SLC18A3CA1CA2CA4TSHR | |
| SCHEMBL3083341 | 1.00 | SLC18A3 (0.46) | SLC18A3CA1CA2CA4TSHR | |
| SCHEMBL3087522 | 1.00 | SLC18A3 (0.46) | SLC18A3CA1CA2CA4TSHR | |
| SCHEMBL2453564 | 1.00 | SLC18A3 (0.46) | SLC18A3CA1CA2CA4TSHR | |
| SCHEMBL3083346 | 1.00 | SLC18A3 (0.46) | SLC18A3CA1CA2CA4TSHR | |
| SCHEMBL11338397 | 0.97 | SLC18A3 (0.44) | SLC18A3CA1CA2CA4TSHR | |
| SCHEMBL11338392 | 0.97 | SLC18A3 (0.44) | SLC18A3CA1CA2CA4TSHR | |
| SCHEMBL11338394 | 0.97 | SLC18A3 (0.44) | SLC18A3CA1CA2CA4TSHR | |
| SCHEMBL23275886 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| WO-2018072602-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | SLC18A3 2528/4885CA1 1419/4885CA2 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.